CAMBRIDGE, U.K. - Sept. 7, 2020 - Biosceptre is pleased to announce that an agreement has been signed with pre-clinical CAR T development company, Carina Biotech, that will see the advancement of a promising cancer immunotherapy.
Biosceptre, a biopharmaceutical company developing targeted therapeutics and immune-oncology products, has acquired the exclusive rights to Carina Biotech's nfP2X7-targeted CAR-T cells and associated intellectual property, which has shown encouraging cancer-killing capacity against a number of cancers in pre-clinical testing.
Biosceptre and Carina will collaborate to further develop the nfP2X7 CAR-T program with the aim of advancing towards clinical trials in the near future. Under the terms of the deal Carina received an upfront cash payment and equity in Biosceptre.
"With this deal we are building on our commitment to therapies focussed on non-functional P2X7, a cancer target that has been shown to be present on the majority of cancers", said Gavin Currie CEO of Biosceptre. "Our goal is to bring novel therapeutics to patients suffering from a wide range of malignancies and CAR-T therapy is an important part of our immune-oncology approach".
Deborah Rathjen, PhD, CEO of Carina Biotech said "This agreement with Biosceptre represents a significant milestone for Carina as it is the first commercial agreement involving our proprietary CAR-T technology. We believe that nfP2X7-targeting CAR-T cells hold significant promise as a potential treatment for a range of solid cancers and we are pleased to be working with Biosceptre to further bolster their pipeline of therapies exploiting the novel nfP2X7 target".
"I would like to pay particular tribute to the Carina Board of Directors, led by our Chair Dr. Leanna Read, for their role in bringing this deal to fruition", Dr Rathjen added.
ABOUT
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that's committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel prize-winning science leadership and renowned researchers, our work is founded on science from the University of Sydney, Australia. Biosceptre is headquartered in the UK and has research laboratories in both Sydney and Cambridge, UK.
Our pioneering team discovered the oncology target nfP2X7 - which is shown to be present on the cell surface of a wide range of tumour types.
https://www.biosceptre.com/
Carina Biotech is an Australian pre-clinical development company focusing on CAR-T therapies to treat cancer. Carina has strong R&D capability across a network of research providers and collaborators, including leading scientists at the Women's & Children's Hospital (Adelaide), the University of South Australia, the University of Adelaide and Seattle Children's Hospital in the United States. Carina is working on developing a number of CAR-Ts and CAR-T complementary technologies.
Contact
Bridget Jackson
